Walleye Capital
STLN

Walleye Capital’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Walleye Capital’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.42M Buy
+445,832
New +$1.87M 0.01% 1355

Other funds holding STLN

Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
KWA
Kingswood Wealth Advisors San Diego, California $2.48B AUM 36.19% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
WPC
White Pine Capital Bloomington, Minnesota $423M AUM 67.01% 1-Year Est. Return
TC
T3 Companies New York $93.7M AUM
SOW
State of Wyoming Cheyenne, Wyoming $989M AUM 52.24% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
IAAG
Innovative Asset Advisors Group Shelton, Connecticut $229M AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Walleye Capital's STLN Position: Q2 2026 in Review

Walleye Capital opened a new position in Starling Oncology Institute, Inc. Common Stock (STLN) in Q2 2026: 445,832 shares worth $2.42M. The stake represents 0.01% of the portfolio and ranks #1355 among its holdings.

29 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • Walleye Capital held 445,832 shares of Starling Oncology Institute, Inc. Common Stock worth $2.42M as of Q2 2026.
  • Starling Oncology Institute, Inc. Common Stock was a new Walleye Capital position in Q2 2026.
  • Starling Oncology Institute, Inc. Common Stock made up 0.01% of Walleye Capital's portfolio in Q2 2026, its #1355 holding.
  • 29 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.